PTGX Protagonist Therapeutics, Inc.

12.00
+0.00  (0%)
Previous Close 12.00
Open 12.07
Price To book 2.70
Market Cap 202.27M
Shares 16,856,000
Volume 117,638
Short Ratio 1.44
Av. Daily Volume 103,508

SEC filingsSee all SEC filings

  1. 8-K - Current report 17899084
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17884821
  3. 8-K - Current report 17875596
  4. 8-K - Current report 17870049
  5. 8-K - Current report 17862618

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b initiation announced January 17, 2017. Interim futility analysis 2H 2017.
PTG-100
Ulcerative colitis

Latest News

  1. Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors
  2. A small biotech wants to disrupt billion-dollar injectable drug markets with a single pill
  3. Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News
  4. Protagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen
  5. Why Protagonist Therapeutics Shares Are Climbing
  6. Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease
  7. Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300
  8. Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity
  9. Protagonist Therapeutics posts 1Q loss
  10. Protagonist Therapeutics Reports First Quarter 2017 Financial Results
  11. Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200
  12. Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week
  13. Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference
  14. Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
  15. Protagonist Therapeutics to Present at the Barclays Global Healthcare Conference
  16. Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidates at European Crohn's and Colitis Organization (ECCO) Congress
  17. Protagonist Therapeutics to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
  18. Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
  19. Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100